Today, there are more biosimilars available to manage psoriatic disease than ever before. A biosimilar is a U.S. Food and Drug Administration (FDA) approved biologic product that is very similar to another FDA-approved biologic reference product. Biosimilars are given through injections or intravenous (IV) infusions.
Request your free resource to learn more about:
- FDA approval of biosimilars and interchangeable products
- Why biosimilars are not called generic versions of a biologic
- Biosimilars available to treat psoriasis and psoriatic arthritis
- Risks and side effects of biosimilars